Loading: 100%
LEXICON PHARMACEUTICALS, INC. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 168 (as per Q2 2015)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker LXRXno data available
Financial year endsFY ends End of no data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 171012141618
datesClosing price (adj.)
13.10.201711.21
11.10.201711.54
04.10.201712.28
27.09.201712.19
20.09.201712.63
13.09.201713.76
06.09.201714.41
30.08.201714.27
23.08.201714.12
16.08.201714.51
09.08.201714.90
02.08.201715.58
26.07.201716.87
19.07.201716.25
12.07.201715.89
05.07.201716.56
27.06.201716.98
20.06.201717.00
13.06.201716.83
06.06.201714.94
30.05.201713.69
23.05.201714.37
16.05.201715.74
09.05.201715.88
02.05.201715.69
25.04.201715.45
18.04.201714.90
11.04.201714.47
04.04.201714.26
28.03.201714.16
21.03.201713.98
14.03.201715.28
07.03.201716.08
28.02.201716.04
21.02.201715.21
14.02.201714.94
07.02.201714.34
31.01.201714.33
24.01.201714.14
17.01.201714.23
10.01.201714.81
03.01.201714.20
27.12.201614.39
19.12.201616.37
12.12.201615.78
05.12.201615.64
28.11.201616.03
21.11.201616.47
14.11.201617.02
07.11.201614.83
31.10.201614.83
24.10.201615.75
17.10.201616.51
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
11.21n/a
Market Capitalisation
in million USD
1,164n/a
Enterprise Value
in million USD
789n/a
Common Shares Outstanding
as per May 2, 2016
103,821,416n/a
Preferred Shares Outstanding
as per May 2, 2016
n/a
Average Basic Shares Outstanding
TTM
n/a
Average Diluted Shares Outstanding
TTM
103,632,500n/a
Index Membership
n/a
Business Summary
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas.
no data available
Key Financials & Ratios (all figures TTM as per Nov 30, -1, million USD, full statements further below)
Profit & Loss
Revenues 141n/a
Gross Profit 141n/a
Operating Income -6n/a
EBITDA -5n/a
Net Profit -11n/a
Balance Sheet
Cash and Cash Equivalents 477n/a
Receivables 1n/a
Total Current Assets 492n/a
PP&E 21n/a
Total Assets 611n/a
Accounts Payable 26n/a
Current Debt 2n/a
Total Current Liabilities 122n/a
Long-Term Debt 101n/a
Total Liabilities 358n/a
Total Equity 253n/a
Cash Flow
Depreciation & Amortisation 1n/a
Change in Working Capital 159n/a
Operating Cash Flow 165n/a
Net Change in PP&E and Intangibles -1n/a
Investing Cash Flow -180n/a
Dividends Paid 0n/a
Financing Cash Flow -2n/a
Total Change in Cash -17n/a
Free Cash Flow 154n/a
Profitability Ratios
Gross Margin 100.0%n/a
Operating Margin -4.2%n/a
Net Profit Margin -8.2%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS -0.11n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value 0.22n/a
Other Ratios
Current Ratio 403.6%n/a
Liabilities to Equity Ratio 141.8%n/a
Debt to Assets Ratio 16.8%n/a
Profit & Loss StatementP&L data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Revenue
11
5
2
1
2
23
130
Sales & Services Revenue
0
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
Cost of revenue
0
0
0
0
0
0
0
Cost of Goods & Services
0
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
Gross Profit
11
5
2
1
2
23
130
Other Operating Income
0
0
0
0
0
0
0
Operating Expenses
-101
-101
-116
-110
-105
-123
-129
Selling, General & Administrative
-19
-19
-17
-17
-17
-19
-24
Selling & Marketing
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
Research & Development
-81
-79
-92
-83
-90
-89
-95
Depreciation & Amortization
0
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
0
Other Operating Expense
0
-3
-7
-10
2
-15
-10
Operating Income (Loss)
-90
-96
-114
-108
-102
-100
1
Non-Operating Income (Loss)
-5
-6
-2
-2
-2
0
-6
Interest Expense, net
-2
-2
-2
-2
-2
-2
-7
Interest Expense
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
0
0
Other Non-Operating Income (Loss)
-3
-4
0
0
0
2
1
Pretax Income (Loss), Adjusted
-95
-102
-116
-110
-104
-100
-5
Abnormal Gains (Losses)
1
0
0
0
0
0
0
Acquired In-Process R&D
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
Pretax Income (Loss)
-93
-102
-116
-110
-104
-100
-5
Income Tax (Expense) Benefit, net
0
0
0
0
0
0
0
Current Income Tax
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
-93
-102
-116
-110
-104
-100
-5
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
-93
-102
-116
-110
-104
-100
-5
Minority Interest
11
0
0
0
0
0
0
Net Income
-83
-102
-116
-110
-104
-100
-5
Preferred Dividends
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
-83
-102
-116
-110
-104
-100
-5
Remarks
restated on Mar 8, 2012 n/a
calculated values,
restated on Mar 11, 2013 n/a
calculated values,
restated on Mar 7, 2014 n/a
calculated values,
restated on Mar 12, 2015 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
Balance SheetBS data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
211
282
223
129
339
521
Cash & Cash Equivalents
n/a
47
186
30
37
137
203
Short Term Investments
n/a
164
95
193
92
202
318
Accounts & Notes Receivable
n/a
1
0
1
1
1
1
Accounts Receivable, Net
n/a
1
0
1
1
1
1
Notes Receivable, Net
n/a
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
Inventories
n/a
0
0
0
0
0
0
Raw Materials
n/a
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
Other Short Term Assets
n/a
3
4
6
5
29
10
Prepaid Expenses
n/a
3
4
6
5
5
10
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
24
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
0
0
0
Total Current Assets
n/a
215
286
231
135
369
532
Property, Plant & Equipment, Net
n/a
53
46
43
41
1
21
Property, Plant & Equipment
n/a
0
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
0
Long Term Investments & Receivables
n/a
0
0
0
0
0
0
Long Term Investments
n/a
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
Other Long Term Assets
n/a
99
98
98
98
101
98
Intangible Assets
n/a
0
0
0
0
0
0
Goodwill
n/a
45
45
45
45
45
45
Other Intangible Assets
n/a
54
54
54
54
53
53
Prepaid Expense
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
1
0
0
0
3
0
Total Noncurrent Assets
n/a
152
145
141
140
102
120
Total Assets
n/a
367
431
372
274
471
652
Liabilities and owners' equity
Payables & Accruals
n/a
9 9423000
20 19828000
17 16583000
17 17389000
23 23184000
44 44482000
Accounts Payable
n/a
3 3159000
6 6042000
8 7661000
10 9715000
13 13064000
20 19725000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
6 6264000
14 13786000
9 8922000
8 7674000
10 10120000
25 24757000
Short Term Debt
n/a
1 1138000
1 1443000
2 1574000
2 1710000
20 20167000
2 1976000
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
0 214000
0 119000
0 128000
0 195000
2 1618000
76 76499000
Deferred Revenue
n/a
0 214000
0 119000
0 128000
0 195000
2 1618000
76 76499000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Total Current Liabilities
n/a
11 10775000
21 21390000
18 18285000
19 19294000
45 44969000
123 122957000
Long Term Debt
n/a
27 27345000
23 23451000
22 21877000
20 20167000
88 87500000
101 100960000
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
82 81740000
88 88103000
65 64938000
65 64536000
55 54889000
142 142193000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
14 14212000
14 14212000
14 13910000
13 13405000
13 12679000
109 109151000
Deferred Tax Liabilities
n/a
19 18745000
19 18745000
19 18745000
19 18745000
19 18675000
19 18675000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
49 48783000
55 55146000
32 32283000
32 32386000
24 23535000
14 14367000
Total Noncurrent Liabilities
n/a
109 109085000
112 111554000
87 86815000
85 84703000
142 142389000
243 243153000
Total Liabilities
n/a
120 119860000
133 132944000
105 105100000
104 103997000
187 187358000
366 366110000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
921 920662000
1,088 1087513000
1,167 1167117000
1,176 1175622000
1,391 1390723000
1,398 1397750000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 -237000
0 -345000
-1 -630000
-2 -1503000
-2 -2390000
-3 -2747000
Retained Earnings
n/a
-673 -673406000
-790 -789621000
-900 -899832000
-1,004 -1003958000
-1,104 -1104252000
-1,109 -1108934000
Other Equity
n/a
0 5000
0 21000
0 23000
0 2000
0 -63000
0 -219000
Equity Before Minority Interest
n/a
247 247024000
298 297568000
267 266678000
170 170163000
284 284018000
286 285850000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
247 247024000
298 297568000
267 266678000
170 170163000
284 284018000
286 285850000
Total Liabilities & Equity
n/a
367 366884000
431 430512000
372 371778000
274 274160000
471 471376000
652 651960000
Remarks restated on n/a restated on Mar 8, 2012 n/a restated on Mar 11, 2013 n/a restated on Mar 7, 2014 n/a restated on Mar 12, 2015 n/a restated on Mar 11, 2016 n/a restated on May 5, 2016 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net Income/Starting Line
-93
-102
-116
-110
-104
-100
-5
Net Income
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Depreciation & Amortization
6
5
5
4
3
2
1
Non-Cash Items
7
13
13
16
5
20
17
Stock-Based Compensation
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
Change in Working Capital
-9
1
10
-5
5
2
172
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
0
Cash from Operating Activities
-89
-82
-88
-94
-91
-76
185
Change in Fixed Assets & Intangibles
0
-1
1
0
-2
2
-1
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
Net Change in Long Term Investment
1
-107
69
-97
101
-111
-116
Decrease in Long Term Investment
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
-6
0
0
0
0
0
Net Cash from Divestitures
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
Other Investing Activities
11
0
0
0
0
0
0
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
Cash from Investing Activities
12
-114
70
-98
100
-108
-117
Dividends Paid
0
0
0
0
0
0
0
Cash From (Repayment of) Debt
36
-38
-4
-1
-2
82
-2
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
55
181
161
38
0
201
0
Increase in Capital Stock
55
181
161
38
1
202
0
Decrease in Capital Stock
0
0
0
0
-1
-1
0
Other Financing Activities
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
Cash from Financing Activities
92
143
157
36
-1
284
-2
Net Cash Before Disc. Operations and FX
15
-53
139
-156
7
100
66
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
Net Cash Before FX
15
-53
139
-156
7
100
66
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
Net Changes in Cash
15
-53
139
-156
7
100
66
Remarks
restated on Mar 8, 2012 n/a
calculated values,
restated on Mar 11, 2013 n/a
calculated values,
restated on Mar 7, 2014 n/a
calculated values,
restated on Mar 12, 2015 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
restated on Mar 11, 2016 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo